A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis

Inclusion Criteria:

• Adult patients, >/= 18 years of age

• Active rheumatoid arthritis (DAS28-ESR > 3.2), according to the revised (1987) ACRcriteria or EULAR/ACR (2010) criteria of > 6 months duration

• Patients with intolerance or inadequate response to methotrexate or other non-biologicDMRADs or inadequate response to a first ant-TNF agent

• Oral corticosteroids (</= 10 mg/day prednisone or equivalent) and non-steroidalanti-inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted ifon a stable dose regimen for >/= 4 weeks prior to baseline

• Permitted non-biologic DMRAD is allowed if at stable dose for at least 4 weeks priorto baseline

• Females of childbearing potential and males with female partners of childbearingpotential must be using a reliable means of contraception as defined by protocolduring the study and for at least 3 months following the last dose ofRoActemra/Actemra

• Patients with intolerance or inadequate response to methotrexate or other non-biologicDMARDs or inadequate response to first anti-TNF agent

Exclusion Criteria:

• Major surgery (including joint surgery) within 8 weeks prior to screening or plannedmajor surgery within 6 months following baseline

• Rheumatic autoimmune disease other than RA or significant systemic involvementsecondary to RA; secondary Sjögren's syndrome with RA is permitted

• Functional Class IV as defined by the ACR Classification of Functional Status inRheumatoid Arthritis

• Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16

• Prior history of current inflammatory joint disease other than RA

• Exposure to tocilizumab (either intravenous [IV] or SC) at any time prior to baseline

• Treatment with any investigational agent with four weeks (or five-half lives of theinvestigational drug, whichever is longer) of screening

• Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline

• Previous treatment with Abatacept

• History of severe allergic of anaphylactic reactions to human, humanized, or murinemonoclonal antibodies

• Evidence of serious uncontrolled concomitant cardiovascular, nervous system,pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disease

• History of diverticulitis, diverticulitis requiring antibiotic treatment, or chroniculcerative lower GI disease such as Crohn's disease, ulcerative colitis, or othersymptomatic lower GI conditions that might predispose to perforation

• Known active current or history of recurrent bacterial, viral, fungal, mycobacterial,or other infections (including but not limited to tuberculosis [TB] and atypicalmycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungalinfections or nail beds)

• Any major episode of infection requiring hospitalization or treatment with IVantibiotics within 4 weeks of screening or oral antibiotics within 2 weeks ofscreening

• Active TB requiring treatment within the previous 3 years

• Positive hepatitis B or hepatitis C

• Primary or secondary immunodeficiency (history of or currently active)

• Evidence of active malignant disease, malignancies diagnosed with the previous 10years (including hematological malignancies and solid tumors, except basal of squamouscell carcinoma of the skin diagnosed within the previous 20 years

• Pregnant and lactating women

• History of alcohol, drug, or chemical abuse within 1 year prior to screening

• Neuropathies or other conditions that might interfere with pain evaluation

• Inadequate hematological, real of liver function